254 related articles for article (PubMed ID: 36048358)
1. Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease.
Galli M; Rollini F; Been L; Zenni MM; Angiolillo DJ; Franchi F
J Thromb Thrombolysis; 2022 Oct; 54(3):461-469. PubMed ID: 36048358
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study.
Franchi F; Rollini F; Aggarwal N; Hu J; Kureti M; Durairaj A; Duarte VE; Cho JR; Been L; Zenni MM; Bass TA; Angiolillo DJ
Circulation; 2016 Sep; 134(11):780-92. PubMed ID: 27559041
[TBL] [Abstract][Full Text] [Related]
3. A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study.
Rollini F; Franchi F; Cho JR; DeGroat C; Bhatti M; Muniz-Lozano A; Singh K; Ferrante E; Wilson RE; Dunn EC; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
Eur Heart J; 2016 Sep; 37(35):2722-30. PubMed ID: 26848148
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
Franchi F; Faz GT; Rollini F; Park Y; Cho JR; Thano E; Hu J; Kureti M; Aggarwal N; Durairaj A; Been L; Zenni MM; Guzman LA; Suryadevara S; Antoun P; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2016 Jun; 9(11):1089-98. PubMed ID: 27013060
[TBL] [Abstract][Full Text] [Related]
5. Impact of timing from blood sampling to pharmacodynamic assessment on measures of platelet reactivity in patients treated with P2Y
Rollini F; Franchi F; Singh K; Cho JR; Bhatti M; DeGroat C; Hu J; Aggarwal N; Alobaidi Z; Thano E; Ferrante E; Zenni M; Bass TA; Angiolillo DJ
Thromb Haemost; 2016 Nov; 116(6):1060-1069. PubMed ID: 27488362
[TBL] [Abstract][Full Text] [Related]
6. Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease.
Franchi F; Rollini F; Been L; Maaliki N; Abou Jaoude P; Rivas A; Zhou X; Jia S; Briceno M; Lee CH; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
Eur Heart J Cardiovasc Pharmacother; 2022 Aug; 8(5):452-461. PubMed ID: 34114623
[TBL] [Abstract][Full Text] [Related]
7. Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study.
Ortega-Paz L; Franchi F; Rollini F; Galli M; Been L; Ghanem G; Shalhoub A; Ossi T; Rivas A; Zhou X; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Jennings LK; Angiolillo DJ
Thromb Haemost; 2024 Mar; 124(3):263-273. PubMed ID: 37224883
[TBL] [Abstract][Full Text] [Related]
8. Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease.
Shang LL; Guo DD; Zhao HY; Quan AJ; Cao PG
J Clin Pharm Ther; 2018 Jun; 43(3):342-347. PubMed ID: 29150850
[TBL] [Abstract][Full Text] [Related]
9. Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention.
Sweeny JM; Angiolillo DJ; Franchi F; Rollini F; Waksman R; Raveendran G; Dangas G; Khan ND; Carlson GF; Zhao Y; Teng R; Mehran R
J Am Heart Assoc; 2017 Mar; 6(4):. PubMed ID: 28356282
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease: Results of the SWAP-4 Study.
Franchi F; Rollini F; Rivas Rios J; Rivas A; Agarwal M; Kureti M; Nagaraju D; Wali M; Shaikh Z; Briceno M; Nawaz A; Moon JY; Been L; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
Circulation; 2018 Jun; 137(23):2450-2462. PubMed ID: 29526833
[TBL] [Abstract][Full Text] [Related]
11. Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients.
Erlinge D; Gurbel PA; James S; Lindahl TL; Svensson P; Ten Berg JM; Foley DP; Wagner H; Brown PB; Luo J; Zhou C; Moser BA; Jakubowski JA; Small DS; Winters KJ; Angiolillo DJ
J Am Coll Cardiol; 2013 Aug; 62(7):577-83. PubMed ID: 23747759
[TBL] [Abstract][Full Text] [Related]
12. Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction.
Kerneis M; Silvain J; Abtan J; Hauguel M; Barthélémy O; Payot L; Brugier D; Galier S; Collet JP; Montalescot G
Arch Cardiovasc Dis; 2015 Oct; 108(10):502-10. PubMed ID: 26113480
[TBL] [Abstract][Full Text] [Related]
13. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.
Angiolillo DJ; Badimon JJ; Saucedo JF; Frelinger AL; Michelson AD; Jakubowski JA; Zhu B; Ojeh CK; Baker BA; Effron MB
Eur Heart J; 2011 Apr; 32(7):838-46. PubMed ID: 21252171
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2).
Angiolillo DJ; Curzen N; Gurbel P; Vaitkus P; Lipkin F; Li W; Jakubowski JA; Zettler M; Effron MB; Trenk D
J Am Coll Cardiol; 2014 Apr; 63(15):1500-9. PubMed ID: 24333493
[TBL] [Abstract][Full Text] [Related]
15. Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study.
Hauguel-Moreau M; Boccara F; Boyd A; Salem JE; Brugier D; Curjol A; Hulot JS; Kerneis M; Galier S; Cohen A; Montalescot G; Collet JP; Silvain J
Eur Heart J; 2017 Jun; 38(21):1676-1686. PubMed ID: 28065907
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction.
Lee YS; Jin CD; Kim MH; Guo LZ; Cho YR; Park K; Park JS; Park TH; Kim YD
Circ J; 2015; 79(6):1248-54. PubMed ID: 25959558
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation.
Cho JR; Rollini F; Franchi F; DeGroat C; Bhatti M; Dunn EC; Ferrante E; Muniz-Lozano A; Suryadevara S; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2015 Jul; 8(8):1075-1083. PubMed ID: 26117466
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity.
Lhermusier T; Lipinski MJ; Tantry US; Escarcega RO; Baker N; Bliden KP; Magalhaes MA; Ota H; Tian W; Pendyala L; Minha S; Chen F; Torguson R; Gurbel PA; Waksman R
Am J Cardiol; 2015 Mar; 115(6):716-23. PubMed ID: 25728845
[TBL] [Abstract][Full Text] [Related]
19. Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
Angiolillo DJ; Franchi F; Waksman R; Sweeny JM; Raveendran G; Teng R; Zhao Y; Carlson G; Khan N; Mehran R
J Am Coll Cardiol; 2016 Feb; 67(6):603-613. PubMed ID: 26868683
[TBL] [Abstract][Full Text] [Related]
20. Switching patients from clopidogrel to prasugrel in acute coronary syndrome: impact of the clopidogrel loading dose on platelet reactivity.
Lhermusier T; Lipinski MJ; Drenning D; Marso S; Chen F; Torguson R; Waksman R
J Interv Cardiol; 2014 Aug; 27(4):365-72. PubMed ID: 25041356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
